JP2007502795A - パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 - Google Patents
パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 Download PDFInfo
- Publication number
- JP2007502795A JP2007502795A JP2006523588A JP2006523588A JP2007502795A JP 2007502795 A JP2007502795 A JP 2007502795A JP 2006523588 A JP2006523588 A JP 2006523588A JP 2006523588 A JP2006523588 A JP 2006523588A JP 2007502795 A JP2007502795 A JP 2007502795A
- Authority
- JP
- Japan
- Prior art keywords
- combination
- active substance
- group
- pharmaceutical preparation
- selegiline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 26
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 18
- 239000004480 active ingredient Substances 0.000 title abstract 4
- 239000013543 active substance Substances 0.000 claims abstract description 130
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 32
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims abstract description 9
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims abstract description 9
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims abstract description 7
- 239000000812 cholinergic antagonist Substances 0.000 claims abstract description 7
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims abstract description 7
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims abstract description 6
- 229940127230 sympathomimetic drug Drugs 0.000 claims abstract description 6
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 32
- 229960003946 selegiline Drugs 0.000 claims description 29
- 239000011159 matrix material Substances 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- -1 pyrivezil Chemical compound 0.000 claims description 11
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229960003179 rotigotine Drugs 0.000 claims description 8
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 8
- 229940052760 dopamine agonists Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims description 6
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 claims description 6
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 5
- 239000000150 Sympathomimetic Substances 0.000 claims description 5
- 229960003089 pramipexole Drugs 0.000 claims description 5
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 5
- 229960001879 ropinirole Drugs 0.000 claims description 5
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 5
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 4
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 4
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims description 4
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims description 3
- BDNMABJZSXTKAQ-VCPDFFEISA-N 3-(diethylamino)propyl (1r,4s)-3-phenylbicyclo[2.2.1]heptane-3-carboxylate Chemical compound CCN(CC)CCCOC(=O)C1([C@H]2CC[C@H](C2)C1)C1=CC=CC=C1 BDNMABJZSXTKAQ-VCPDFFEISA-N 0.000 claims description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 3
- 229930003347 Atropine Natural products 0.000 claims description 3
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 3
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims description 3
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 claims description 3
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003805 amantadine Drugs 0.000 claims description 3
- 229960004046 apomorphine Drugs 0.000 claims description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 3
- 229960000396 atropine Drugs 0.000 claims description 3
- 229940092732 belladonna alkaloid Drugs 0.000 claims description 3
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 3
- 229960000911 benserazide Drugs 0.000 claims description 3
- 229960001081 benzatropine Drugs 0.000 claims description 3
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 3
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 claims description 3
- GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical compound CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 claims description 3
- 229960001793 bornaprine Drugs 0.000 claims description 3
- 229960002802 bromocriptine Drugs 0.000 claims description 3
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 3
- 229960004596 cabergoline Drugs 0.000 claims description 3
- 229960004205 carbidopa Drugs 0.000 claims description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 3
- 239000003954 decarboxylase inhibitor Substances 0.000 claims description 3
- 238000009792 diffusion process Methods 0.000 claims description 3
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 3
- 229960003337 entacapone Drugs 0.000 claims description 3
- 229960003587 lisuride Drugs 0.000 claims description 3
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 3
- 229960004640 memantine Drugs 0.000 claims description 3
- MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 claims description 3
- 229960005103 metixene Drugs 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 claims description 3
- 229960003941 orphenadrine Drugs 0.000 claims description 3
- 150000007925 phenylethylamine derivatives Chemical class 0.000 claims description 3
- 229960005253 procyclidine Drugs 0.000 claims description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 3
- 229960002646 scopolamine Drugs 0.000 claims description 3
- 229960004558 terguride Drugs 0.000 claims description 3
- 229960001032 trihexyphenidyl Drugs 0.000 claims description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- 229940124639 Selective inhibitor Drugs 0.000 claims description 2
- 229960002274 atenolol Drugs 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 238000010030 laminating Methods 0.000 claims description 2
- 229960004851 pergolide Drugs 0.000 claims description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims description 2
- 229960002508 pindolol Drugs 0.000 claims description 2
- 229960003712 propranolol Drugs 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 6
- 239000010410 layer Substances 0.000 description 20
- 238000002648 combination therapy Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 6
- 239000002585 base Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000012661 Dyskinesia Diseases 0.000 description 3
- 239000004831 Hot glue Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229920005601 base polymer Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 229960003678 selegiline hydrochloride Drugs 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 description 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- KQHZEKNQJJSVDN-KVVVOXFISA-N 2-(2-hydroxyethylamino)ethanol;(z)-octadec-9-enoic acid Chemical compound OCCNCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KQHZEKNQJJSVDN-KVVVOXFISA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 230000000768 catecholaminergic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 108010009400 levodopa receptor Proteins 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical group 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10338174A DE10338174A1 (de) | 2003-08-20 | 2003-08-20 | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| PCT/EP2004/009136 WO2005018619A1 (de) | 2003-08-20 | 2004-08-14 | Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011275858A Division JP5827114B2 (ja) | 2003-08-20 | 2011-12-16 | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007502795A true JP2007502795A (ja) | 2007-02-15 |
Family
ID=34201721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523588A Withdrawn JP2007502795A (ja) | 2003-08-20 | 2004-08-14 | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
| JP2011275858A Expired - Lifetime JP5827114B2 (ja) | 2003-08-20 | 2011-12-16 | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011275858A Expired - Lifetime JP5827114B2 (ja) | 2003-08-20 | 2011-12-16 | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8980308B2 (enExample) |
| EP (1) | EP1656122B2 (enExample) |
| JP (2) | JP2007502795A (enExample) |
| KR (1) | KR20060065692A (enExample) |
| CN (1) | CN1832732A (enExample) |
| AT (1) | ATE446744T1 (enExample) |
| AU (1) | AU2004266063B2 (enExample) |
| BR (1) | BRPI0412054A (enExample) |
| CA (1) | CA2535063C (enExample) |
| DE (2) | DE10338174A1 (enExample) |
| DK (1) | DK1656122T4 (enExample) |
| ES (1) | ES2335771T5 (enExample) |
| IL (1) | IL173712A (enExample) |
| MX (1) | MXPA06001815A (enExample) |
| NZ (1) | NZ545593A (enExample) |
| PL (1) | PL1656122T5 (enExample) |
| PT (1) | PT1656122E (enExample) |
| RU (1) | RU2397757C2 (enExample) |
| SI (1) | SI1656122T2 (enExample) |
| WO (1) | WO2005018619A1 (enExample) |
| ZA (1) | ZA200509779B (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010525018A (ja) * | 2007-04-24 | 2010-07-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物 |
| JP2012092127A (ja) * | 2003-08-20 | 2012-05-17 | Lts Lohmann Therapie-Systeme Ag | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
| JP2015508798A (ja) * | 2012-03-01 | 2015-03-23 | ファーネクストＰｈａｒｎｅｘｔ | パーキンソン病の治療のための新規治療方法 |
| JP7063537B2 (ja) | 2014-05-20 | 2022-05-09 | エルテーエス ローマン テラピー－ジステーメ アーゲー | ラベンダー油を含有する経皮治療システム |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| CN102816157B (zh) | 2005-07-26 | 2016-05-18 | 比艾尔-坡特拉有限公司 | 作为comt抑制剂的硝基儿茶酚衍生物 |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| LT2481410T (lt) | 2007-01-31 | 2016-11-10 | Bial - Portela & Ca., S.A. | Nitrokatecholio dariniai kaip komt inhibitoriai vartojami konkrečiu dozavimo režimu |
| RU2326660C1 (ru) * | 2007-03-14 | 2008-06-20 | Закрытое акционерное общество "Биологические исследования и системы" | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) |
| EP2322168A1 (en) * | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
| JP6165412B2 (ja) * | 2008-07-29 | 2017-07-19 | ノヴィファーマ，エス．アー． | ニトロカテコールの投与計画 |
| US9132094B2 (en) | 2009-04-01 | 2015-09-15 | Bial—Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
| KR101292768B1 (ko) * | 2010-04-23 | 2013-08-05 | 아이큐어 주식회사 | 경피 흡수 제제 |
| EP2563347B1 (en) | 2010-04-30 | 2016-10-12 | Teikoku Pharma USA, Inc. | Propynylaminoindan transdermal compositions |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| WO2012129429A2 (en) | 2011-03-24 | 2012-09-27 | Teikoku Pharma Usa, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| CA2841785A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| EP2776020B1 (en) | 2011-11-09 | 2019-09-11 | Teikoku Seiyaku Co., Ltd. | Methods for the treatment of skin neoplasms |
| CA2858025C (en) | 2011-12-13 | 2020-09-22 | Bial-Portela & Ca., S.A. | 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-2-hydroxy-3-methoxy-1-nitrobenzene as an intermediate to prepare a catechol-o-methyltransferase inhibitor |
| US20130197023A1 (en) * | 2012-01-27 | 2013-08-01 | California Institute Of Technology | Neuroprotection by pharmacological chaperoning of nicotinic acetylcholine receptors |
| KR20150059177A (ko) | 2012-11-02 | 2015-05-29 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 프로피닐아미노인단 경피 조성물 |
| JP2016523918A (ja) * | 2013-06-27 | 2016-08-12 | シーダーズ−サイナイ メディカル センター | 神経変性状態の予防および治療のためのアドレナリン受容体拮抗薬 |
| CN103622997A (zh) * | 2013-11-22 | 2014-03-12 | 内蒙古医科大学 | 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物 |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| CN104510725B (zh) * | 2015-01-22 | 2021-04-27 | 中国药科大学 | 一种普拉克索周效透皮贴剂及其制备方法 |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| WO2018067163A1 (en) * | 2016-10-07 | 2018-04-12 | Transwell Biotech Co., Ltd. | Pramipexole transdermal delivery system and uses thereof |
| JP2020503950A (ja) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 経皮薬剤送達の装置及び方法 |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| JP7420797B2 (ja) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | 薬剤送達の方法及びシステム |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| JP2022529353A (ja) | 2019-04-17 | 2022-06-21 | コンパス パスファインダー リミテッド | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 |
| US20240299501A1 (en) * | 2023-03-06 | 2024-09-12 | Xygenyx Inc. | Composition and methods of treatment using transdermal hormone supplementation |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62249923A (ja) * | 1986-04-16 | 1987-10-30 | デグツサ・アクチエンゲゼルシヤフト | パ−キンソン病、うつ病、ナルコレプシ−および脳器官精神症候群の抑制用薬剤およびその製造方法 |
| JPH11506744A (ja) * | 1995-06-07 | 1999-06-15 | ノウブン ファーマシューティカルズ インク． | 室温で液体である低分子量薬を含む経皮組成物 |
| JPH11209271A (ja) * | 1998-01-23 | 1999-08-03 | Nitto Denko Corp | 経皮吸収製剤 |
| JP2000514053A (ja) * | 1996-07-02 | 2000-10-24 | ヘクサル・アクチェンゲゼルシャフト | ペルゴリドの経皮投与用硬膏 |
| JP2001039865A (ja) * | 1995-04-26 | 2001-02-13 | Theratech Inc | 経皮的投与のためのマトリックスパッチ |
| WO2002015889A1 (de) * | 2000-08-24 | 2002-02-28 | Neurobiotec Gmbh | Transdermales therapeutisches system zur behandlung des restless-legs-syndroms |
| JP2002097137A (ja) * | 2000-07-19 | 2002-04-02 | Junichi Sudo | パーキンソン病の予防および／または治療剤 |
| WO2002089777A1 (en) * | 2001-05-08 | 2002-11-14 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of parkinson's disese |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| JPH0611698B2 (ja) | 1984-12-19 | 1994-02-16 | 大正製薬株式会社 | 貼付剤 |
| US4666441A (en) * | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
| DE3710966A1 (de) | 1986-04-16 | 1987-12-03 | Degussa | Synergistische kombination von amantadin und selegilin |
| US4877618A (en) * | 1988-03-18 | 1989-10-31 | Reed Jr Fred D | Transdermal drug delivery device |
| GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| WO1994002176A1 (en) * | 1992-07-28 | 1994-02-03 | The Procter & Gamble Company | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
| US5462746A (en) * | 1992-11-02 | 1995-10-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation |
| DE4332094C2 (de) | 1993-09-22 | 1995-09-07 | Lohmann Therapie Syst Lts | Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung |
| US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| GB9511366D0 (en) | 1995-06-06 | 1995-08-02 | Smithkline Beecham Plc | Novel formulations |
| US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
| US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| RO121628B1 (ro) | 1999-02-05 | 2008-01-30 | Cipla Limited | Compoziţie medicinală, topică, pulverizabilă,dozator care o conţine, procedeu de realizare a dozatorului şi utilizarea compoziţiei menţionate |
| US6465004B1 (en) | 1999-06-05 | 2002-10-15 | Noven Pharmaceuticals, Inc. | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use |
| DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| FR2798065B1 (fr) | 1999-09-02 | 2003-09-05 | Assist Publ Hopitaux De Paris | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| US20030119884A1 (en) * | 2000-11-01 | 2003-06-26 | Epstein Mel H. | Methods and compositions for regulating memory consolidation |
| DE10064453A1 (de) | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| CA2381630A1 (en) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
| EP1344522A1 (en) | 2001-05-08 | 2003-09-17 | Schwarz Pharma Ag | Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
-
2003
- 2003-08-20 DE DE10338174A patent/DE10338174A1/de not_active Withdrawn
-
2004
- 2004-08-14 CA CA2535063A patent/CA2535063C/en not_active Expired - Fee Related
- 2004-08-14 PT PT04764129T patent/PT1656122E/pt unknown
- 2004-08-14 AT AT04764129T patent/ATE446744T1/de active
- 2004-08-14 KR KR1020067003176A patent/KR20060065692A/ko not_active Ceased
- 2004-08-14 AU AU2004266063A patent/AU2004266063B2/en not_active Ceased
- 2004-08-14 MX MXPA06001815A patent/MXPA06001815A/es active IP Right Grant
- 2004-08-14 ES ES04764129T patent/ES2335771T5/es not_active Expired - Lifetime
- 2004-08-14 EP EP04764129A patent/EP1656122B2/de not_active Expired - Lifetime
- 2004-08-14 PL PL04764129T patent/PL1656122T5/pl unknown
- 2004-08-14 WO PCT/EP2004/009136 patent/WO2005018619A1/de not_active Ceased
- 2004-08-14 US US10/568,941 patent/US8980308B2/en active Active
- 2004-08-14 RU RU2005141214/15A patent/RU2397757C2/ru not_active IP Right Cessation
- 2004-08-14 DK DK04764129.5T patent/DK1656122T4/da active
- 2004-08-14 NZ NZ545593A patent/NZ545593A/en not_active IP Right Cessation
- 2004-08-14 DE DE502004010303T patent/DE502004010303D1/de not_active Expired - Lifetime
- 2004-08-14 SI SI200431317T patent/SI1656122T2/sl unknown
- 2004-08-14 CN CNA2004800225495A patent/CN1832732A/zh active Pending
- 2004-08-14 JP JP2006523588A patent/JP2007502795A/ja not_active Withdrawn
- 2004-08-14 BR BRPI0412054-0A patent/BRPI0412054A/pt not_active IP Right Cessation
-
2005
- 2005-12-02 ZA ZA200509779A patent/ZA200509779B/en unknown
-
2006
- 2006-02-13 IL IL173712A patent/IL173712A/en not_active IP Right Cessation
-
2011
- 2011-12-16 JP JP2011275858A patent/JP5827114B2/ja not_active Expired - Lifetime
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62249923A (ja) * | 1986-04-16 | 1987-10-30 | デグツサ・アクチエンゲゼルシヤフト | パ−キンソン病、うつ病、ナルコレプシ−および脳器官精神症候群の抑制用薬剤およびその製造方法 |
| JP2001039865A (ja) * | 1995-04-26 | 2001-02-13 | Theratech Inc | 経皮的投与のためのマトリックスパッチ |
| JPH11506744A (ja) * | 1995-06-07 | 1999-06-15 | ノウブン ファーマシューティカルズ インク． | 室温で液体である低分子量薬を含む経皮組成物 |
| JP2000514053A (ja) * | 1996-07-02 | 2000-10-24 | ヘクサル・アクチェンゲゼルシャフト | ペルゴリドの経皮投与用硬膏 |
| JPH11209271A (ja) * | 1998-01-23 | 1999-08-03 | Nitto Denko Corp | 経皮吸収製剤 |
| JP2002097137A (ja) * | 2000-07-19 | 2002-04-02 | Junichi Sudo | パーキンソン病の予防および／または治療剤 |
| WO2002015889A1 (de) * | 2000-08-24 | 2002-02-28 | Neurobiotec Gmbh | Transdermales therapeutisches system zur behandlung des restless-legs-syndroms |
| WO2002089777A1 (en) * | 2001-05-08 | 2002-11-14 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of parkinson's disese |
Non-Patent Citations (3)
| Title |
|---|
| JPN6012014613; ＳＣＨＡＰＩＲＡ，Ａ．Ｈ．: 'Ｄｏｐａｍｉｎｅ ａｇｏｎｉｓｔｓ ａｎｄ ｎｅｕｒｏｐｒｏｔｅｃｔｉｏｎ ｉｎ Ｐａｒｋｉｎｓｏｎ'ｓ ｄｉｓｅａｓｅ' Ｅｕｒ Ｊ Ｎｅｕｒｏｌ Ｖｏｌ．９ Ｓｕｐｐｌ ３, 2002, ｐ．７-１４ |
| JPN6014015303; 'Ｐａｒｋｉｎｓｏｎ病における薬物療法の新しい工夫 -ＭＡＯ-Ｂ阻害薬塩酸セレギリン療法' 医学のあゆみ 第１９９巻第４号, 20011027, ２８９-２９２頁 |
| JPN7010002648; ＲＵＰＮＩＡＫ，Ｎ．Ｍ． ｅｔ ａｌ: 'Ｔｈｅｒａｐｅｕｔｉｃ ｅｆｆｉｃａｃｙ ｏｆ ａ ｎｏｖｅｌ ｔｒａｎｓｄｅｒｍａｌ ｄｅｌｉｖｅｒｙ ｓｙｓｔｅｍ ｆｏｒ （＋）-ＰＨＮＯ ｉｎ ｐａｒｋｉｎｓｏｎｉａｎ ｓｑｕｉｒｒｅｌ ｍｏ' Ｊ Ｎｅｕｒｏｌ Ｎｅｕｒｏｓｕｒｇ Ｐｓｙｃｈｉａｔｒｙ Ｖｏｌ．５２， Ｎｏ．２, 1989, ｐ．２８９-９０ * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012092127A (ja) * | 2003-08-20 | 2012-05-17 | Lts Lohmann Therapie-Systeme Ag | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
| US8980308B2 (en) | 2003-08-20 | 2015-03-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal pharmaceutical preparation containing active substance combinations, for treating Parkinson's disease |
| JP2010525018A (ja) * | 2007-04-24 | 2010-07-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物 |
| JP2015508798A (ja) * | 2012-03-01 | 2015-03-23 | ファーネクストＰｈａｒｎｅｘｔ | パーキンソン病の治療のための新規治療方法 |
| JP2018008975A (ja) * | 2012-03-01 | 2018-01-18 | ファーネクストＰｈａｒｎｅｘｔ | パーキンソン病の治療のための新規治療方法 |
| JP2018184461A (ja) * | 2012-03-01 | 2018-11-22 | ファーネクストＰｈａｒｎｅｘｔ | パーキンソン病の治療のための新規治療方法 |
| JP7063537B2 (ja) | 2014-05-20 | 2022-05-09 | エルテーエス ローマン テラピー－ジステーメ アーゲー | ラベンダー油を含有する経皮治療システム |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5827114B2 (ja) | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 | |
| JP7153010B2 (ja) | 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 | |
| JP4925823B2 (ja) | プラミペキソール活性剤を含む経皮治療システム | |
| JP2010159302A (ja) | レストレスレッグス症候群を処置するための経外角皮的投与形 | |
| TWI764173B (zh) | 含羅替戈汀之貼附劑 | |
| EP3730129B1 (en) | Rotigotine-containing patch | |
| WO2009152777A1 (zh) | 稳定的释药可控的雷沙吉兰透皮贴片及其制备方法 | |
| JP2017519837A (ja) | 経皮送達システム | |
| US20160184246A1 (en) | Transdermal drug delivery systems for agomelatine | |
| TW202045157A (zh) | 羅替戈汀安定化方法 | |
| TWI876275B (zh) | 含羅替戈汀之貼附劑 | |
| CN117157062A (zh) | 抑制药物结晶的透皮贴剂及其制备方法 | |
| JP2018535225A (ja) | 経皮薬剤送達のためのシステムおよび方法 | |
| US20040081682A1 (en) | Transdermal system (tds) that contain inhibitors of phosphodiesterase lV | |
| CN101180018B (zh) | 用于治疗恶心的经皮的方法和贴片 | |
| US20210145761A1 (en) | Transdermal delivery system containing a dopamine agonist | |
| WO2024040860A1 (zh) | 抑制结晶的罗替高汀透皮给药系统及其制备方法和用途 | |
| HK40002940B (zh) | 包含哌甲酯或其盐的透皮递送系统及其方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101130 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110131 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110228 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111219 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120105 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120316 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131016 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131021 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131115 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131216 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140722 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140725 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140808 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140813 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140919 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141022 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20150212 |